Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Investigative Dermatology - Volume 132, Issue 10, October 2012, Pages 2466-2469

Kim A. Papp, Cathy Reid, Peter Foley, Rod Sinclair, David H. Salinger, Gary Williams, Hua Dong, James G. Krueger, Chris B. Russell, David A. Martin,